We are committed to improving health and well-being around the world. From developing new therapies that treat and prevent disease to helping people in need, we are guided by a rich legacy and inspired by a shared vision.
With an enduring focus on innovation and sound science, we work to deliver vaccines, medications, and consumer and animal health products that can help millions around the world.
Oncology Information Center
New Book to Feature Hundreds of Full-Color Images
Merck announced today that the Tenth Edition of The Merck Veterinary Manual, a comprehensive reference on animal health for veterinary professionals, has now been released.
First published in 1955, The Merck Veterinary Manual addresses diagnosis, treatment, and prevention of diseases in companion, food, exotic, wild, and laboratory animals. Over 400 veterinary experts from 19 countries contributed to this latest edition which is published as an educational partnership with Merial Limited.
"The goal of The Merck Veterinary Manual has always been to provide concise and authoritative information on all common diseases of animals likely to be seen by veterinarians," said editor of The Merck Veterinary Manual, Cynthia M. Kahn, B.A., M.A., of Merial Limited. "This new edition reflects both the remarkable advances in veterinary science and the emergence of new pathogens and diseases since the previous edition."
For the first time, The Merck Veterinary Manual, a hardcover book, features hundreds of full-color graphics, including illustrations, photomicrographs, and radiographic, ultrasonographic, and endoscopic images. Every chapter of the new manual has been reviewed and updated to reflect the latest findings in medicine and clinical practice.
Ten new chapters have been added to provide information on emerging issues of importance to veterinarians, including the cloning of domestic animals, complementary and alternative veterinary medicine, and diseases and disorders such as equine metabolic syndrome, disorders of potassium metabolism, seminal vesiculitis in bulls, and pseudopregnancy in goats.
The Tenth Edition reflects the increasing knowledge base regarding exotic and laboratory animals with expanded coverage of pet birds, fish, ratites, reptiles, and rodents.
A chapter on African hedgehogs has been added to reflect their growing popularity as pets.
The extensive Zoonoses reference table has also been updated with new introductory material, recent zoonoses, and cross references to more complete discussions. In addition, the zoonotic potential of veterinary diseases has been highlighted throughout the text. Other sections that have been extensively revised include toxicology, immunology, and behavior.
The pharmacology section includes content on drug actions and pharmacodynamics, veterinary dosage forms and delivery systems, and chemical residues in food. More than 60 tables in this section provide information on topics such as drug treatments and potencies, laboratory tests, and parasites.
Published as a service to the scientific community, The Tenth Edition of The Merck Veterinary Manual sells for $60.00 and is available at leading bookstores, by calling toll-free at 877-762-2974, or via the Internet at www.merckbooks.com.
Merck also publishes The Merck/Merial Manual for Pet Health, The Merck Manual of Diagnosis and Therapy, The Merck Manual of Patient Symptoms, The Merck Manual Home Health Handbook, The Merck Manual of Health and Aging, and The Merck Index.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
Merck Forward-Looking Statement
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2009 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).